Kintara announces 1-for-35 reverse stock split in connection with TuHURA merger

Written by Emily J. Thompson, Senior Investment Analyst

KTRA%

Updated: Oct 16 2024

0mins

Reverse Stock Split Announcement: Kintara Therapeutics has approved a 1-for-35 reverse stock split, with trading on the Nasdaq under the new name TuHURA Biosciences and symbol "HURA" starting October 18, following a merger.
Immuno-Oncology Developments: TuHURA Biosciences is focused on developing innovative cancer immunotherapy technologies, including a Phase 3 trial for its personalized vaccine candidate IFx-2.0 in treating advanced Merkel Cell Carcinoma.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Kintara announces 1-for-35 reverse stock split in connection with TuHURA merger

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

ComEd Submits 2028-2031 Grid Plan with Over $13 Billion in Investments

New Era Energy Partners with Primary Digital to Develop Texas Data Centers Exceeding 1GW

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch